ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,466Medicare Part D Prescriptions Filled, Including Refills

Rank: 97 out of 387

$600K Total Retail Price of All Prescriptions

Rank: 104 out of 387

201 Patients Receiving at Least One Drug in Part D
52%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

27% of this provider’s 201 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

64% of this provider’s 201 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

5% of this provider’s 4,411 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

52 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
HYDROCODONE-ACETAMINOPHEN 842 243 S3 1 1
CARISOPRODOL 584 132 R 2 53
LISINOPRIL 544 258 3 3
OMEPRAZOLE 447 193 4 4
SIMVASTATIN 415 202 5 5
METOPROLOL SUCCINATE 353 215 6 18
FUROSEMIDE 330 160 7 7
AMITRIPTYLINE HCL 274 60 R 8 62
NAPROXEN 273 74 9 89
FENOFIBRATE 253 108 10 106
CYMBALTA 228 41 11 44
LEVOTHYROXINE SODIUM 214 131 12 2
POTASSIUM CHLORIDE 212 89 13 9
DIGOXIN 183 80 14 40
METFORMIN HCL 179 92 15 8
MORPHINE SULFATE ER 176 40 S2 16 79
CRESTOR 168 67 17 34
PROAIR HFA 158 33 18 47
ATORVASTATIN CALCIUM 134 76 19 13
SERTRALINE HCL 133 20 20 23
METOPROLOL TARTRATE 130 80 21 11
ZOLPIDEM TARTRATE 115 74 22 16
ZETIA 106 36 23 96
PREDNISONE 92 63 24 43
ADVAIR DISKUS 88 30 25 41
GLIPIZIDE 85 43 26 63
COMBIVENT 85 32 26 133
OXYCONTIN 85 0 S2 26 92
ALENDRONATE SODIUM 82 48 29 31
TAMSULOSIN HCL 78 72 30 32
CILOSTAZOL 74 48 31 218
WARFARIN SODIUM 73 41 32 17
PRAVASTATIN SODIUM 71 58 33 15
GABAPENTIN 70 21 34 10
LYRICA 69 12 35 66
PHENYTOIN SODIUM EXTENDED 69 0 35 107
QUINAPRIL HCL 67 67 37 174
CARVEDILOL 67 20 37 21
PROPRANOLOL HCL 66 0 39 100
FENTANYL 64 23 S2 40 80
PREMARIN 63 27 R 41 77
ENDOCET 61 27 S2 42 147
CITALOPRAM HBR 61 0 42 19
SINGULAIR 57 20 44 83
ALLOPURINOL 53 45 45 28
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 7, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.